Xintela (XINT) Investing in Life Science 2025 summary

Company overview and platform focus

• Clinical-stage biopharma develops stem cell therapies and targeted cancer therapies via a subsidiary, with current focus on stem cell product XSTEM for osteoarthritis and other indications.

• Proprietary selection technology uses integrin α10β1 marker to isolate pure, potent MSCs, enhancing product quality and consistency.

• In-house GMP facility provides manufacturing control, flexibility, cost reduction, and generates revenue through services for other cell therapies.

Clinical study results and product efficacy

• Final results from phase I/IIa osteoarthritis study show XSTEM is safe and delivers sustained positive efficacy two years post-treatment.

• Highest dose (16 million MSCs) halted cartilage degradation and improved bone structure, with no adverse events at any dose.

• Significant pain reduction and improved knee function reported by patients, with effects lasting up to 24 months after a single injection.

• Data support disease-modifying potential, with highest dose showing best therapeutic effect.

Pipeline, expansion, and future plans

• XSTEM platform has granted patents for all therapeutic uses and is being studied in other indications, including difficult-to-heal wounds and acute respiratory distress syndrome.

• Ongoing partnering and licensing discussions, with a recent collaboration license agreement for horse MSCs.

• Next steps include new clinical studies in osteoarthritis, expanding GMP services, and completing wound healing studies.